This phase 3b , multinational , open-label , randomized , parallel-group , multicenter study evaluated the safety of a 4-dose series of MenACWY-CRM , a quadrivalent meningococcal conjugate vaccine , concomitantly administered with routine vaccinations to healthy infants .